Zeniplatin is a bioactive compound. References: Aamdal S, Bruntsch U, Kerger J, Verweij J, ten Bokkel Huinink W, Wanders J, Rastogi R, Franklin HR, Kaye SB. Zeniplatin in advanced malignant melanoma and renal cancer: phase II studies with unexpected nephrotoxicity. Cancer Chemother Pharmacol. 1997;40(5):439-43. PubMed PMID: 9272122.

纯度：≥98%

CAS：111490-36-9